{"status": "OK", "response": {"docs": [{"type_of_material": "Chronology", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Bad news has been dogging Bristol-Myers Squibb for months, and yesterday things grew worse. A new study of Vanlev, a treatment for heart failure from Bristol-Myers, found the drug to be only marginally more effective than enalapril, an inexpensive generic version of Merck's Vasotec, a blockbuster of yesteryear. Shares of the Bristol-Myers Squibb Company fell $7.57, or more than 15 percent, to $41.08, in heavy trading yesterday as pharmaceutical analysts lowered their ratings and swallowed earlier hopes that Vanlev could be a billion-dollar seller that would rejuvenate the company's aging product line.", "headline": {"main": "Market Place; Heart-drug test delivers the latest blow to Bristol-Myers."}, "abstract": "Study by Milton Packer, cardiologist at College of Physicians and Surgeons of Columbia University, shows Vanlev, treatment for heart failure from Bristol-Myers Squibb, is only marginally more effective than enalapril, inexpensive generic version of Merck & Co's drug Vasotec; shares of Bristol-Myers fall $7.57, or more than 15 percent, to $41.08, in heavy trading as pharmaceutical analysts lower their ratings and swallow earlier hopes that Vanlev could be billion-dollar seller that would rejuvenate company's aging product line; graph (Market Place column) (M)", "print_page": "7", "word_count": 712, "_id": "4fd26da68eb7c8105d827368", "snippet": "Bad news has been dogging Bristol-Myers Squibb for months, and yesterday things grew worse. A new study of Vanlev, a treatment for heart failure from Bristol-Myers, found the drug to be only marginally more effective than enalapril, an inexpensive...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/03/21/business/market-place-heart-drug-test-delivers-the-latest-blow-to-bristol-myers.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "MARKET PLACE (TIMES COLUMN)"}, {"name": "persons", "value": "PACKER, MILTON"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "COLUMBIA UNIVERSITY"}, {"name": "organizations", "value": "BRISTOL-MYERS SQUIBB CO"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "GENERIC AND BRAND NAME PRODUCTS"}, {"name": "subject", "value": "ENALAPRIL (DRUG)"}, {"name": "subject", "value": "RATINGS AND RATING SYSTEMS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "VASOTEC (DRUG)"}, {"name": "subject", "value": "VANLEV (DRUG)"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Milt", "lastname": "Freudenheim"}], "original": "By Milt Freudenheim"}, "document_type": "article", "pub_date": "2002-03-21T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Researchers have found that they can sharply reduce the death rate in high-risk heart attack patients with small but costly devices that are tucked under the skin of the chest and can avert potentially fatal heart rhythms. The devices, implantable defibrillators, sense when the heart's rhythm is going awry and administer a small electric shock to the heart to bring its fluttering rhythm back to normal, preventing sudden death. The new study found that the device was effective in patients whose hearts were so damaged from heart attacks that they could no longer pump blood effectively.", "headline": {"main": "Tiny Heart Devices Reduce Death Rate, But Cost Is Concern"}, "abstract": "Researchers find they can sharply reduce death rate in high-risk heart attack patients with implantable defibrilators, small but costly devices that are tucked under skin of chest and can avert potentially fatal heart rhythms; implantable defibrilators are routinely used for relatively small group of patients who, like Vice Pres Dick Cheney, have demonstrable heart-rhythm disturbances, and in - these cases insurers and Medicare cover cost, which is $20,000 for device and other $10,000 to insert it surgically; new study, which was paid for by device's manufacturer, Guidant Corp, shows that it is effective in much larger group of people who have had serious heart attacks that place them at risk for heart-rhythm disturbances, but may not have had such problems; raises questions about how to provide these patients with devices and and how to pay for it (M)", "print_page": "1", "word_count": 1061, "_id": "4fd22cb18eb7c8105d7b89db", "snippet": "Researchers have found that they can sharply reduce the death rate in high-risk heart attack patients with small but costly devices that are tucked under the skin of the chest and can avert potentially fatal heart rhythms.    The devices, implantable...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2002/03/20/us/tiny-heart-devices-reduce-death-rate-but-cost-is-concern.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "CHENEY, DICK"}, {"name": "organizations", "value": "GUIDANT CORP"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "UNITED STATES POLITICS AND GOVERNMENT"}, {"name": "subject", "value": "HEALTH INSURANCE"}, {"name": "subject", "value": "IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "SURGERY AND SURGEONS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2002-03-20T00:00:00Z", "section_name": "Front Page; Health; U.S.; Washington"}], "meta": {"hits": 2, "offset": 0, "time": 40}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}